Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.
Shishir Sinha Qualigen Therapeutics (NASDAQ:QLGN) appointed Shishir Sinha, the company’s newly promoted SVP and current COO, to lead its diagnostics division, FastPack. “With the return of the sales and...